Bristol Myers Squibb Company Profile

What is the competitive landscape for BRISTOL MYERS SQUIBB

BRISTOL MYERS SQUIBB has seventy approved drugs.

There are twelve US patents protecting BRISTOL MYERS SQUIBB drugs.

There are five hundred and ninety-seven patent family members on BRISTOL MYERS SQUIBB drugs in fifty-one countries and one hundred and forty-four supplementary protection certificates in eighteen countries.

Summary for Bristol Myers Squibb

International Patents:	597
US Patents:	12
Tradenames:	60
Ingredients:	55
NDAs:	70

Drugs and US Patents for Bristol Myers Squibb

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	AZACTAM IN PLASTIC CONTAINER	aztreonam	INJECTABLE;INJECTION	050632-003	May 24, 1989		DISCN	No	No
Bristol Myers Squibb	COUMADIN	warfarin sodium	TABLET;ORAL	009218-022	Mar 1, 1990		DISCN	Yes	No
Bristol Myers Squibb	COUMADIN	warfarin sodium	TABLET;ORAL	009218-018	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Bristol Myers Squibb	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes	10,610,125
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-002	Jun 28, 2006	AB	RX	Yes	No

Expired US Patents for Bristol Myers Squibb

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-003	Jun 29, 2006	7,189,740
Bristol Myers Squibb	REYATAZ	atazanavir sulfate	CAPSULE;ORAL	021567-004	Oct 16, 2006	5,849,911*PED
Bristol Myers Squibb	SERZONE	nefazodone hydrochloride	TABLET;ORAL	020152-002	Dec 22, 1994	4,338,317*PED
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-001	Sep 17, 1998	6,939,964*PED
Bristol Myers Squibb	VIDEX	didanosine	TABLET, CHEWABLE;ORAL	020154-003	Oct 9, 1991	5,616,566*PED

Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	2.5 mg and 20 mg		2016-07-12
	Capsules	100 mg and 150 mg		2010-03-19
	Tablets	600 mg		2009-04-09
	Nasal Spray	4 mg/spray		2016-07-15
	Tablets	2.5 mg and 5 mg		2016-12-28
	Tablets	20 mg, 50 mg, 70 mg and 100 mg		2010-06-28
	Tablets	80 mg and 140 mg		2011-06-17
	Delayed-release Capsules	200 mg, 250 mg and 400 mg		2004-06-01
	Capsules	5 mg, 10 mg and 15 mg		2010-08-30
	Capsules	300 mg		2009-07-20
	Capsules	200 mg		2010-02-16
	Capsules	50 mg, 100 mg and 200 mg		2016-11-03
	Tablets	0.5 mg and 1 mg		2010-06-14
	Tablets	30 mg		2005-06-01
	Tablets	80 mg and 140 mg		2011-06-16
	Capsules	25 mg		2010-07-12

International Patents for Bristol Myers Squibb Drugs

Country	Patent Number	Estimated Expiration
Canada	2505131
Germany	60233335
Japan	2017031216
Serbia	20080517
South Korea	101310427

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1169038	132013902119320	Italy		PRODUCT NAME: DASATINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(SPRYCEL); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/06/363/001 A EU/I/06/363/015, 20061120
2487163	17C1000	France		PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET ATAZANAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER LE SULFATE D'ATAZANAVIR; REGISTRATION NO/DATE: EU/1/15/1025 20150715
2782584	301153	Netherlands		PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406
1427415	C20110017 00045	Estonia		PRODUCT NAME: ELIQUIS - APIKSABAAN; REG NO/DATE: C(2011)3595 18.05.2011
1453521	C201630040	Spain		PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bristol
• Bristol Myers
• Bristol Myers Squibb
• Bristol-myers
• Bristol-myers Squibb

Bristol Myers Squibb: A Pharmaceutical Powerhouse in the Competitive Landscape

In the ever-evolving world of pharmaceuticals, Bristol Myers Squibb (BMS) stands as a titan, navigating the complex terrain of drug development, market dynamics, and fierce competition. As we delve into the company's market position, strengths, and strategic insights, we'll uncover how BMS maintains its edge in this high-stakes industry.

The BMS Advantage: A Legacy of Innovation

Bristol Myers Squibb's journey to the top of the pharmaceutical industry is a testament to its unwavering commitment to innovation. With a history spanning over a century, BMS has consistently pushed the boundaries of medical science, developing groundbreaking therapies that have transformed patient care.

A Diverse Portfolio: The Cornerstone of Success

At the heart of BMS's success lies its diverse product portfolio. The company's offerings span multiple therapeutic areas, including:

1. Oncology
2. Hematology
3. Immunology
4. Cardiovascular
5. Neuroscience

This diversification not only mitigates risk but also positions BMS to capitalize on emerging medical needs across various sectors.

"Bristol Myers Squibb posted revenues of $48.3 billion, an increase of 7%, or 9% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and higher demand for Eliquis, partially offset by the impact of generics on Sprycel, Revlimid and Abraxane."[1]

Key Revenue Drivers: The Stars of the Show

BMS's financial success is largely attributed to its star performers in the market. Leading the charge are:

1. Opdivo (nivolumab): A groundbreaking immunotherapy drug
2. Eliquis (apixaban): A widely prescribed anticoagulant
3. Revlimid (lenalidomide): A powerhouse in hematological malignancies treatment

These products have not only generated substantial revenue but have also solidified BMS's reputation as a leader in their respective therapeutic areas.

R&D: The Engine of Growth

In the pharmaceutical industry, the adage "innovate or perish" holds particularly true. BMS has taken this to heart, investing heavily in research and development to fuel its pipeline and maintain its competitive edge.

Investment in Innovation

In 2017, BMS invested a staggering $4.8 billion in pharmaceutical R&D, representing 23.1% of its pharmaceutical sales[5]. This substantial commitment to innovation underscores the company's long-term vision and dedication to addressing unmet medical needs.

Strategic Collaborations: Expanding Horizons

BMS recognizes that innovation doesn't happen in isolation. The company has forged strategic partnerships and collaborations with academic institutions, biotech firms, and other industry players to enhance its R&D capabilities and accelerate drug development.

Global Footprint: Reaching Patients Worldwide

BMS's global presence is a key factor in its market dominance. With operations spanning multiple countries, the company has established a robust infrastructure to develop, manufacture, and distribute its products on a global scale.

Market Penetration

BMS's products are available in virtually every country in the world, with its largest markets including:

1. United States (55% of 2017 sales)
2. Europe (24% of 2017 sales)
3. Rest of the World (18% of 2017 sales)
4. Other (3% of 2017 sales)[5]

This global reach not only diversifies revenue streams but also allows BMS to tap into emerging markets with high growth potential.

Competitive Landscape: Navigating Choppy Waters

While BMS enjoys a strong market position, it operates in a highly competitive industry. The company faces stiff competition from pharmaceutical giants such as Pfizer, Merck, and Johnson & Johnson[4].

Competitive Advantages: BMS's Secret Sauce

Despite the intense competition, BMS maintains several competitive advantages:

1. Strong R&D Pipeline: Ensures a steady flow of innovative products
2. Focus on High-Growth Areas: Particularly in oncology and immunology
3. Global Presence: Enables market diversification and expansion
4. Strategic Partnerships: Enhances capabilities and creates synergies
5. Strong Brand Reputation: Builds trust among healthcare professionals and patients

Strategic Initiatives: Charting the Course for Future Growth

To maintain its competitive edge and drive future growth, BMS has implemented several strategic initiatives:

1. Expanding the Growth Portfolio

BMS is focusing on expanding its Growth Portfolio, which includes promising new therapies and existing products with growth potential. In 2024, the Growth Portfolio revenues reached $22.6 billion, increasing 17% (19% adjusting for foreign exchange)[1].

2. Strategic Productivity Initiative

BMS has expanded its Strategic Productivity Initiative, aiming to deliver approximately $2 billion in additional cost savings by the end of 2027[1]. This initiative will help optimize operations and improve profitability.

3. Focus on Key Therapeutic Areas

The company continues to prioritize research and development in its core therapeutic areas: oncology, hematology, immunology, cardiovascular, and neuroscience[2]. This focused approach allows BMS to maintain leadership in these critical fields.

4. Digital Transformation

BMS is embracing digital technologies to enhance drug discovery, improve clinical trial efficiency, and optimize manufacturing processes. This digital transformation is crucial for maintaining competitiveness in an increasingly tech-driven industry.

5. Emerging Markets Expansion

Recognizing the growth potential in emerging markets, BMS is strategically expanding its presence in these regions. This expansion not only drives revenue growth but also helps address unmet medical needs in developing countries.

Challenges on the Horizon: Navigating Potential Pitfalls

While BMS's outlook is generally positive, the company faces several challenges that could impact its future performance:

1. Patent Expirations

Like all pharmaceutical companies, BMS must contend with patent expirations on key products. As patents expire, generic competition can significantly erode market share and revenues.

2. Pricing Pressures

Increasing scrutiny on drug pricing, particularly in the United States, could impact BMS's profit margins. The company must navigate these pressures while maintaining its commitment to innovation and patient access.

3. Regulatory Hurdles

The pharmaceutical industry is heavily regulated, and changes in regulatory requirements or delays in drug approvals can significantly impact BMS's pipeline and revenue projections.

4. Intense Competition

The pharmaceutical landscape is highly competitive, with both established players and emerging biotech companies vying for market share. BMS must continuously innovate to maintain its competitive edge.

Future Outlook: Positioning for Sustained Growth

Despite these challenges, BMS's future outlook remains promising. The company's strong pipeline, strategic initiatives, and focus on high-growth therapeutic areas position it well for sustained growth.

"We made good progress in 2024, which was capped by a fourth quarter of strong topline growth driven by key products and important pipeline advancements. We also achieved the landmark U.S. approval of Cobenfy last year for the treatment of schizophrenia in adults, and we expect this medicine to have a meaningful impact on patients and the company as a new growth driver," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb.[1]

Key Takeaways

1. Bristol Myers Squibb maintains a strong market position through its diverse product portfolio and focus on high-growth therapeutic areas.
2. The company's substantial investment in R&D and strategic collaborations fuel its innovation pipeline.
3. BMS's global presence allows it to tap into diverse markets and mitigate regional risks.
4. Strategic initiatives, including cost-saving measures and digital transformation, position BMS for future growth.
5. While facing challenges such as patent expirations and pricing pressures, BMS's strong pipeline and strategic focus provide a solid foundation for sustained success.

FAQs

1. Q: What are Bristol Myers Squibb's main revenue-generating products? A: BMS's main revenue-generating products include Opdivo (nivolumab), Eliquis (apixaban), and Revlimid (lenalidomide).

2. Q: How does Bristol Myers Squibb invest in research and development? A: BMS invests in R&D through internal research centers, collaborations with academic institutions and biotech firms, and strategic acquisitions to bolster its pipeline.

3. Q: What are the key strengths of Bristol Myers Squibb in the pharmaceutical industry? A: Key strengths include a diverse product portfolio, a strong R&D pipeline, strategic acquisitions, and a global market presence.

4. Q: How is Bristol Myers Squibb addressing the challenge of patent expirations? A: BMS is focusing on expanding its Growth Portfolio, investing in R&D to develop new innovative therapies, and pursuing strategic acquisitions to offset potential revenue losses from patent expirations.

5. Q: What is Bristol Myers Squibb's approach to emerging markets? A: BMS is strategically expanding its presence in emerging markets to drive revenue growth and address unmet medical needs in developing countries.

Sources cited: [1] https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_financials/quarterly_reports/2024/BMY-Q42024-Earnings-Press-Release.pdf [2] https://www.bms.com/business-development.html [3] https://pitchgrade.com/companies/bristol-myers-squibb [4] https://canvasbusinessmodel.com/blogs/competitors/bristol-myers-squibb-competitive-landscape [5] https://www.bms.com/about-us/our-impact/economic-responsibility/performance.html